Ilyang presents updated phase II clinical results for Supect at 2012 ASH annual meeting

Published: 2012-12-19 06:56:00

Updated: 2012-12-19 06:56:00

Ilyang and its collaborators Monday provided phase II clinical presentations on Supect (radotinib) at the annual meeting of the American Society of Hematology (ASH), which held on Atlanta between December 8 and 12.

The clinical results, which was presented by professor Kim Sung-hyun of Dong-A ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK